Biotechnology company developing virus-like particle (VLP) vaccines against infectious diseases.
Icosavax, Inc. is a biopharmaceutical company specializing in the development of innovative vaccines to combat infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company focuses primarily on addressing life-threatening respiratory diseases.
At the forefront of its pipeline are several promising vaccine candidates. IVX-121, currently in Phase 1/1b clinical trials, targets respiratory syncytial virus (RSV), a significant cause of respiratory infections. Another candidate, IVX-A12, aims at developing a monovalent antigen for RSV and human metapneumovirus (hMPV), addressing a critical unmet medical need in respiratory health.
Further expanding its portfolio, Icosavax is advancing IVX-241, targeting hMPV, which poses significant health risks, especially to vulnerable populations. Additionally, the company is developing IVX-411, an original receptor binding domain (RBD) sequence antigen designed to combat SARS-CoV-2, currently undergoing Phase 1/2 clinical trials.
Founded in 2017 and headquartered in Seattle, Washington, Icosavax continues to push the boundaries of vaccine innovation, aiming to transform the landscape of infectious disease prevention with its robust pipeline and cutting-edge VLP technology.